Calithera Biosciences, Inc. (CALA) Shares Sold by ClariVest Asset Management LLC
ClariVest Asset Management LLC lessened its stake in Calithera Biosciences, Inc. (NASDAQ:CALA) by 6.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,474 shares of the biotechnology company’s stock after selling 3,295 shares during the period. ClariVest Asset Management LLC owned 0.14% of Calithera Biosciences worth $779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new position in Calithera Biosciences in the second quarter valued at $120,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Calithera Biosciences during the second quarter worth about $166,000. KCG Holdings Inc. acquired a new stake in shares of Calithera Biosciences during the first quarter worth about $144,000. Paloma Partners Management Co acquired a new stake in shares of Calithera Biosciences during the first quarter worth about $160,000. Finally, GAM Holding AG acquired a new stake in shares of Calithera Biosciences during the second quarter worth about $206,000. Institutional investors own 71.03% of the company’s stock.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 16.30% of the company’s stock.
Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) opened at $10.25 on Wednesday. Calithera Biosciences, Inc. has a 12-month low of $2.90 and a 12-month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.02 million. research analysts forecast that Calithera Biosciences, Inc. will post -0.77 earnings per share for the current fiscal year.
CALA has been the subject of several recent research reports. BidaskClub downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. William Blair initiated coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They set an “outperform” rating for the company. Finally, Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Calithera Biosciences has an average rating of “Buy” and a consensus target price of $15.17.
TRADEMARK VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Shares Sold by ClariVest Asset Management LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/calithera-biosciences-inc-cala-shares-sold-by-clarivest-asset-management-llc/1719598.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.